EU/3/02/096

Table of contents

About

On 13 March 2002, orphan designation (EU/3/02/096) was granted by the European Commission to Swedish Orphan AB, Sweden, for nitisinone for the treatment of alkaptonuria.

In May 2014, the sponsor changed name to Swedish Orphan Biovitrum AB (publ).

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
nitisinone
Disease / condition
Treatment of alkaptonuria
Date of first decision
13/03/2002
Outcome
Positive
EU designation number
EU/3/02/096

Sponsor's contact details

Swedish Orphan Biovitrum AB (publ)
SE 112 76 Stockholm
Sweden
Tel. +46 8697 2000
E-mail: mail.se@sobi.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating